StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Celgene's (CELG) Otezla Receives FDA Orphan Status for Treatment of Pediatric Patients with UC
January 18, 2018 3:04 PM
Celgene's (NASDAQ: CELG) Otezla received FDA orphan drug designation for treatment of pediatric patients with ulcerative ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Next Articles
Celgene (CELG) Reports Investigational Data Evaluating ABRAXANE Regimen for Patients with Locally Advanced Pancreatic Cancer
January 22, 2018 5:40 AM